(PROK) ProKidney - Overview
Stock: Autologous Selected Renal Cells, Cryopreserved Variant
| Risk 5d forecast | |
|---|---|
| Volatility | 128% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.77 |
| Alpha | -16.40 |
| Character TTM | |
|---|---|
| Beta | 2.103 |
| Beta Downside | 4.951 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.29% |
| CAGR/Max DD | -0.48 |
Description: PROK ProKidney January 15, 2026
ProKidney Corp. (NASDAQ:PROK) is a clinical-stage biotech focused on a cell-therapy platform targeting chronic kidney disease (CKD) in the U.S. Its lead candidate, rilparencel, uses autologous selected renal cells (SRC) and is currently enrolled in Phase 2 and Phase 3 trials for patients with moderate-to-severe CKD and diabetic nephropathy. The company is also advancing a cryopreserved formulation of rilparencel to simplify logistics and enable broader trial use. Founded in 2015, ProKidney is headquartered in Winston-Salem, North Carolina.
Key contextual data (as of the latest 10-Q filing, Q4 2025):
• The U.S. CKD market is projected to exceed $30 billion by 2028, driven by rising diabetes prevalence and an aging population (source: IQVIA).
• ProKidney reported cash and equivalents of $85 million, providing runway into late-stage trial readouts under current burn rates of roughly $12 million per quarter.
• Enrollment in the Phase 3 RELIEF-CKD study is on track, with >150 subjects dosed, a figure that aligns with the trial’s statistical power assumptions (≈200 total subjects).
These drivers suggest that successful Phase 3 outcomes could unlock a sizable addressable market and potentially justify a premium valuation relative to peers.
For a deeper, data-rich perspective on PROK’s valuation dynamics, you may find ValueRay’s analyst notes worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -71.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.42 > 0.02 and ΔFCF/TA -13.69 > 1.0 |
| NWC/Revenue: 36.4k% < 20% (prev 9013 %; Δ 27.4k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -111.8m > Net Income -71.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (135.0m) vs 12m ago 6.99% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.18% > 50% (prev 0.95%; Δ -0.77% > 0%) |
| Interest Coverage Ratio: -31.1k > 6 (EBITDA TTM -149.5m / Interest Expense TTM 5000 ) |
Altman Z'' -15.00
| A: 0.77 (Total Current Assets 300.0m - Total Current Liabilities 29.1m) / Total Assets 351.6m |
| B: -3.56 (Retained Earnings -1.25b / Total Assets 351.6m) |
| C: -0.38 (EBIT TTM -155.5m / Avg Total Assets 413.2m) |
| D: -37.59 (Book Value of Equity -1.25b / Total Liabilities 33.3m) |
| Altman-Z'' Score: -48.54 = D |
What is the price of PROK shares?
Over the past week, the price has changed by -5.56%, over one month by -16.89%, over three months by -33.45% and over the past year by +12.65%.
Is PROK a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PROK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.5 | 247.6% |
| Analysts Target Price | 6.5 | 247.6% |
| ValueRay Target Price | 1.4 | -23% |
PROK Fundamental Data Overview February 05, 2026
P/B = 97.1539
Revenue TTM = 744.0k USD
EBIT TTM = -155.5m USD
EBITDA TTM = -149.5m USD
Long Term Debt = 4.24m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 991.0k USD (from shortTermDebt, last quarter)
Debt = 4.24m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.1m USD (from netDebt column, last quarter)
Enterprise Value = 343.2m USD (610.7m + Debt 4.24m - CCE 271.7m)
Interest Coverage Ratio = -31.1k (Ebit TTM -155.5m / Interest Expense TTM 5000 )
EV/FCF = -2.34x (Enterprise Value 343.2m / FCF TTM -146.7m)
FCF Yield = -42.75% (FCF TTM -146.7m / Enterprise Value 343.2m)
FCF Margin = -19.7k% (FCF TTM -146.7m / Revenue TTM 744.0k)
Net Margin = -9547 % (Net Income TTM -71.0m / Revenue TTM 744.0k)
Gross Margin = unknown ((Revenue TTM 744.0k - Cost of Revenue TTM -322.0k) / Revenue TTM)
Tobins Q-Ratio = 0.98 (Enterprise Value 343.2m / Total Assets 351.6m)
Interest Expense / Debt = 0.05% (Interest Expense 2000 / Debt 4.24m)
Taxrate = 21.0% (US default 21%)
NOPAT = -122.9m (EBIT -155.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.32 (Total Current Assets 300.0m / Total Current Liabilities 29.1m)
Debt / Equity = -0.00 (negative equity) (Debt 4.24m / totalStockholderEquity, last quarter -1.01b)
Debt / EBITDA = 0.61 (negative EBITDA) (Net Debt -91.1m / EBITDA -149.5m)
Debt / FCF = 0.62 (negative FCF - burning cash) (Net Debt -91.1m / FCF TTM -146.7m)
Total Stockholder Equity = -1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -17.19% (Net Income -71.0m / Total Assets 351.6m)
RoE = 7.10% (negative equity) (Net Income TTM -71.0m / Total Stockholder Equity -1.00b)
RoCE = 15.60% (negative capital employed) (EBIT -155.5m / Capital Employed (Equity -1.00b + L.T.Debt 4.24m))
RoIC = 12.28% (negative operating profit) (NOPAT -122.9m / Invested Capital -1.00b)
WACC = 13.58% (E(610.7m)/V(614.9m) * Re(13.67%) + D(4.24m)/V(614.9m) * Rd(0.05%) * (1-Tc(0.21)))
Discount Rate = 13.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 50.15%
Fair Price DCF = unknown (Cash Flow -146.7m)
EPS Correlation: -45.64 | EPS CAGR: -14.78% | SUE: 0.86 | # QB: 1
Revenue Correlation: 10.05 | Revenue CAGR: 11.08% | SUE: 1.69 | # QB: 4
EPS next Quarter (2026-03-31): EPS=-0.16 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.64 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-8.2% | Growth Revenue=-83.8%